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1. Introduction 
 
              Major epidemiological studies from recent years 
clearly indicate that chronic renal disease has become a very 
significant public health challenge globally, affecting 10 to 14% 
of the population in developed countries and causing substantial 
expenditures. More than a half of patients have a glomerular 
filtration rate (GFR) of less than 60 mL/min; however, no more 
than 1 to 2% are in the highest severity group with end stage 
renal failure. This is explained by a highly accelerated 
atherosclerosis, owing to which the majority of patients die 
before renal replacement therapy could be started. Patients 
started on dialysis as late as in stage 5 chronic kidney disease 
face the highest levels of mortality, with a cause structure 
primarily dominated by deaths from severe cardiovascular 
morbidity. It has been known since an analysis by Foley that 
cardiac mortality in dialysis patients is 10 to 20 times greater 
than in the average population. Cardiac mortality may be 
reduced to as low as a fraction of this level after successful 
renal transplantation but it still remains at 3 to 5 times above the 
reference range of the average population. In his studies based 
on the USRD database, Meier-Kriesche points out that post-
transplant mortality as well as kidney graft survival are 
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correlated with the length of time in ESRD and time spent on 
the waiting list. The leading causes of death in patients who die 
with a functional kidney allograft are cardiovascular diseases, 
which constitute nearly 40% of fatalities. Obesity, diabetes, 
dyslipidemia, hypertension, immunosuppressive therapy, and 
smoking are high-risk factors for the development of 
cardiovascular diseases. Short-term results of renal 
transplantation improved in the last two decades: one-year 
survival exceeds 80%, five-year survival is at 77%, and 10-year 
graft survival is at 56% in Europe. Renal transplantation 
success is characterized by post-transplant overall survival and 
quality of life of patients; kidney graft survival is a parameter 
specific to transplantation. The latter is made up of two 
components: graft loss may occur due to the recipient’s death 
while the renal function is still intact; and also due to a loss of 
graft function, which is referred to as mortality-adjusted graft 
loss and is comprised of re-transplantation and recourse to 
dialysis. Renal transplantation success factors include surgical 
technique, occurrence of surgical complications, and the 
number of previous transplantation attempts in the recipient’s 
medical history. Outcomes with early arterial and venous 
vascular complications are poor as they lead to renal graft loss 
in no less than 30 to 50% of cases; however, their effects are 
negligible since their reported frequency is very low at around 
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1%. The nature of renal transplantation as an intervention 
explains the presence of further risk factors: 
immunosuppression, surgical complications, and infections. 
The circumstances of the intervention determine what we call 
the center effect. Highlights of factors on the recipient’s side 
include age, BMI, co-morbidities, delayed graft function (DGF, 
formerly referred to as ATN – a histological diagnosis), the 
former one being a condition that requires dialysis in the first 
few weeks), length of prior dialysis period, smoking, level of 
education, and social status. Rao et al have concluded that 
patients older than 70 years have the same relative risk of death 
on their 125th post-transplant day as dialysis patients on the 
waiting list; however, cumulative survival in the 4th year after 
transplantation is 66% compared to 51% in those still on 
dialysis. In a study by Heldal et al, transplant patients aged over 
70 years grafted after the year 2000 had a 5-year survival of 
66%, while the figure for those on the waiting list was only 
33%. In all age groups, live donor transplantations are likely to 
produce the most extra years of life gained. Recipients under 55 
years of age receiving from SCD (standard criteria donors) have 
a much greater number of years of life gained, even after 
lengthy prior dialysis. Life expectancy of patients over 65 is 
strongly determined by the length of dialysis; these patients 
benefit from rapid transplantation, even if this makes an ECD 
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(expanded criteria donor) necessary (ET: senior program). A 
prognostic index by Molnár et al indicates that when it comes to 
the clinical selection algorithm, expanded criteria donor kidneys 
should not be coupled with high-risk recipients; this assessment 
can be facilitated by consulting www.Txscores.org. COMMIT 
(Consensus on Managing Modifiable Risk in Transplantation) 
guidelines report that even though short-term outcomes of renal 
transplantation improved considerably over the last two 
decades, long-term survival fails to follow this trend. Kaboré et 
al recently published a systematic review of publications from 
the period of 2005 through 2015 summarizing models 
estimating outcomes of transplanted renal grafts. The definition 
of graft failure varied across different models, and quite a 
number of predictors were evaluated including serum 
creatinine, eGFR, proteinuria, acute rejection, acute tubular 
necrosis, carotid pulse wave velocity, and the 
immunosuppression used. Most models determine 
discrimination performance using receiver operating 
characteristics (ROC) analysis.   
              The number of patients returning to dialysis due to 
chronic damage to the grafted kidney is on the rise. The fifth 
most common reason behind starting renal replacement therapy 
is graft loss (DAGL: dialysis after graft loss), which is why the 
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treatment of this group of patients in clinical practice is 
important. There is a lack of unified guidelines on optimal 
timing of renal replacement therapy initiation, type of modality, 
immunosuppressive therapy withdrawal schemes, transplanted 
kidney removal, and repeat transplantation. The optimal timing 
of renal replacement therapy initiation is also unclear. 
According to a study by Molnár et al, early start of dialysis had 
no benefit for patients in a poorer condition and in the young 
age group; however, in women it was associated with increased 
risk of mortality. As to dialysis modality, the analysis of 
peritoneal versus hemodialysis survival showed no difference 
either in the early (<2 years) or the late (>2 years) mortality 
subgroup. Patients returning to dialysis due to graft loss are 
characterized by the following: 1. their survival data and quality 
of life are worse than those of non-transplanted, incident CKD 
waiting list patients; 2. there is no clear basis for when it is 
optimal to start dialysis; 3. survival is equal in hemodialysis and 
peritoneal dialysis.   
              The classic indications of graftectomy in acute 
complications are as follows: a. arterial/venous thrombosis; b. 
treatment-resistant acute rejection; c. graft rupture; d. 
hemorrhagic complications of biopsy; e. acute septic 
complications; f. primary non-function graft; g. graft 
malignancy. In chronic graft failure: a. graft swelling 
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accompanied by pain upon reduction of immunosuppression; b. 
hematuria; c. subfebrility, fever; d. ESA resistant anemia, 
malnutrition-inflammation syndrome (MICS); e. late-onset 
septic complication; f. recurrent renal disease; g. preparation for 
third renal Tx. The literature is ambivalent about whether 
graftectomy is beneficial in DAGL. In early (1 year) kidney 
graft failure, graftectomy increased the risk of mortality, while 
in late (>1 year) kidney graft failure, patients undergoing 
graftectomy had lower risk of mortality and sepsis. Graftectomy 
patients’ level of immunization (anti-HLA PRA) increased, 
which may reduce the chance of re-transplantation. Ayus et al 
have concluded that graftectomy was associated with a lower 
risk of mortality both in early (>1 day, <1 year) and late-onset 
DAGL. Long-term graft survival is limited partly by the 
patient’s death, and partly by conditions conducive to chronic 
allograft dysfunction.  
           Number of studies about cardiovascular screening of 
high-risk patients are known, but dialysed and transplanted 
patients are underrepresented in these. The guidelines for 
cardiovascular risk assessment also vary. Categorizing patients 
as high, medium, and low risk may help day-to-day care and 
optimal drug treatment. The Courage study compared the 
number of angina events occurring post-intervention and under 
optimal medical therapy. In cases with a GFR above 40, this 
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produced remarkably good results. The incidence of coronary 
artery disease in asymptomatic patients with chronic kidney 
damage is elevated, with at least one coronary artery with a 
stenosis of greater than 50% being present in 37 to 53% of 
them. End-stage kidney disease patients are underrepresented in 
randomized, controlled studies, and receive guideline-approved 
cardioprotective medications at a suboptimal dose due to an 
adverse side effect profile (hemorrhagic complications, 
calciphylaxis). The guidelines of the Hungarian Society of 
Cardiology and the Hungarian Transplantation Society for the 
diagnostic workup in coronary artery disease are different. In 
our work, the 2014 guidelines of the American College of 
Cardiology and the guidelines on non-cardiac surgery of the 
European Society of Cardiology were used for waiting list 
placements.  
 
 
2. Objectives 
 
 
2.1. My research objective was to gain understanding of survival 
and its modifying factors in transplant recipients at UD MHSC.  
First, I validated an existing Spanish prognostic function on a 
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group of patients grafted at the UD MHSC Transplantation Center 
between 1991 and 15-09-2004; the function is used to estimate the 
risks involved in renal transplantation from a compound effect of 
various predictive factors. We assessed the calibration and 
discrimination performance of the function. 
2.2. We analyzed the survival of patients returning to dialysis due 
to graft failure from chronic damage to the transplanted kidney, 
comparing it to that of hemodialysis recipients with no 
transplantation.  We examined the indications of graftectomy and 
the histopathology of removed grafts.  
We also analyzed the effect of graftectomy on repeat 
transplantation since no clear verdict exists from literature data so 
far as to whether or not elective graftectomy is beneficial, since it 
mainly acts as an immunizer in re-transplantation candidates, 
which represents an elevated immunological risk, while in those 
unfit for re-transplantation, it may offer a survival advantage. 
2.3. Thirdly the aim of our study was to describe a novel approach 
of cardiovascular screening and management of dialysis patients 
evaluated for the transplant waiting list. 
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3. Subject and methods 
3.1 a. Study poplualtion 
 
Based on the published prognostic function, we estimated the 
5-year risk of death in 339 cadaver kidney transplant patients 
(18 years old or older) undergoing a transplant between 1 
January 1991 and 15 September 2004 at the Center of 
Transplantation of the Medical and Health Science Centre 
University of Debrecen, who were discharged from the 
hospital and followed until death or 15 September 2009. 
Second and third kidney recipients and those patients who had 
received organs other than kidney were excluded from the 
study. Routine immunosuppression therapy consisted of 
calcineurin inhibitors (cyclosporinA or tacrolimus), 
mycophenolate mofetil and steroid. Immunologically highrisk 
patients received antithymocyte globulin or anti-IL2-R 
induction therapy. 
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3.1.b. Data collection 
 
Patient data were collected retrospectively by chart review. 
The predictors in the prognostic function to be validated were 
age, serum creatinine level, time on dialysis, vascular 
calcification, diabetes before transplantation, pretransplant CV 
disease, left ventricular hypertrophy and acute tubular 
necrosis. We defined predictors the same way as in the study 
in which the prognostic function was derived. Left ventricular 
hypertrophy was determined by echocardiographic or 
electrocardiographic criteria, hypertension as blood pressure 
higher than 140/90 mmHg or being on antihypertensive 
therapy. Vascular calcification was evaluated by preoperative 
X-ray of the aortoiliac region; pretransplant CV disease 
included ischemic heart disease, cerebral vascular disease and 
peripheral vascular disease. Ischemic heart disease was 
defined as myocardial infarction documented by elevated 
enzyme levels, with or without electrocardiographic changes 
or coronary artery revascularization. Cerebral vascular disease 
was defined as transient ischemic attack or stroke. Peripheral 
vascular disease was considered if revascularization 
procedures or amputations had been performed. Follow-up 
data were obtained annually from the general practitioners of 
the patients and from the dialysis centers of the 4 Hungarian 
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counties where the patients lived. The data published about the 
prognostic function would not have allowed us to perform the 
validation study. The authors of the paper provided us with the 
estimated 5-year risk of death in patients with no risk factors; 
this made it possible to estimate the 5-year risk for each 
person in our study population. 
 
3.1.c Statistical analysis 
 
We first assessed how well the prognostic function estimated 
the number of deaths that occurred within 5 years of follow-
up. For this purpose, we used 2 methods. First, we compared 
the predicted 5-year risk of death with the actual 5-year 
cumulative incidence of death in deciles of predicted risk. 
Further, we added up the predicted risks to calculate the 
expected number of deaths and compared it with the observed 
number of deaths in the deciles of the predicted risk. We tested 
the difference of the observed and the expected numbers of 
deaths using the Hosmer-Lemeshow test. Secondly, to avoid 
the (imitation that cumulative incidences can be calculated in 
only a limited number of groups, preventing direct comparison 
13 
 
of the actual occurrence of death to certain values of the 
predicted risk, we applied smoother to obtain a nonparametric 
estimate of the 5-year cumulative incidence of death by robust 
locally weighted regression. We used a tricube weight 
function and a bandwidth of 0.5. We plotted this 
nonparametric estimate of risk - which is based on the actual 
occurrence of death in each person and influenced by the 
occurrence of death in persons with similar estimated risk 
against the estimate of risk provided by the prognostic 
function.To see how the function would separate participants 
who died and who survived during follow-up, we calculated 
the area under the receiver operating characteristic (ROC) 
curve. A discriminating function yields a wide range of 
predieted risk and assigns higher predicted risk to participants 
who will die than to participants who will not die within 5 
years. The better the discrimination, the larger is the area 
under the ROC curve. Additionally, we fitted a Cox 
proportional hazard model with the same predictors as in the 
original model which we validated to see the difference in the 
strength of association between the predictors and the risk of 
death in our dataset compared with the derivation dataset. 
Finally we extended the model with some other potential 
predictors to see whether they can improve the performance of 
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the model. These predictors were cold ischemia time, HLA 
match (less than 4 or at least 4), sex and hemoglobin level. 
  
 
 
 
3.2.a Selection and Description of Participants 2. 
 
Demographic data were collected on all patients 
retrospectively by chart review at baseline. We enrolled 180 
patients who started dialysis between 2000-2005, of whom 
123 had had no kidney transplantation previously, 12% were 
waiting-listed for transplantation and 57 were transplanted 
patients with graft failure (20 of them (35%) were waiting-
listed again). In Hungary the proportion of waiting-listed 
patients is rather low. That derives not only from inadequate 
patient education but also from the low activity for deceased 
donor kidney transplants. Transplanted patients received a 
cadaver kidney between 1991 and 2002 in the Centre of 
Transplantation, Medical & Health Science Centre, University 
of Debrecen. Recipients who received organs other than 
kidneys, and patients younger than 18 years were excluded 
from the study. Laboratory data obtained at baseline included 
the following: hemoglobin levels (Hb), GFR, calcium (Ca), 
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phosphate (P), cholesterol (chol), triglycerides (Tg). Follow-
up data were obtained annually from the general practitioners 
of the patients and also from the dialysis centres of the four 
Hungarian counties where the patients lived. They were 
followed till death or till 15 December 2010.  Resected kidney 
transplant specimens were routinely sent to the pathology 
department for microscopic examination. Specimens were 
subjected to standard histologic review by a staff pathologist 
using routine techniques. We used Kaplan-Meier analysis and 
log-rank test to compare the survival of patients in the HD, in 
the reHD groups from the start of the dialysis. We adjusted for 
age and gender in Cox-regression. We performed a similar 
analysis to compare the survival of patients with graft failure 
whose graft was removed (43 patients) and those whose graft 
was not removed (14 patients). Additionally, we compared the 
clinical characteristics of patients in the HD and reHD groups. 
We used the two-sample t-test to compare continuous and the 
χ2-test to compare categorical variables.  
  
3.3.a Selection and Description of   Participants 3. 
 
Detailed clinical and demographic data were collected from 
the initial transplant assessment. All candidates underwent a 
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structured medical assessment by a consistent group of 
transplant physicians before activating the transplant waiting 
list. This assessment included a medical history, physical 
examination, lipid profile, fasting glycemia, resting 
electrocardiogram (ECG) and chest radiograph, and cardiac 
ultrasound. All 28 study patients were interviewed by a 
cardiologist to determine the presence of cardiovascular 
disease and assess the perioperative cardiovascular risk. We 
put our patients on a wait list between July 2013 and July 
2014. 
3.3.b Classification of Cardiac Risk 
Patients were classified into 3 groups according to their risk, 
on the basis of the following 3 factors: age, history of diabetes, 
or ischemic heart disease . High-risk patients (n=8) displayed 
active ischemic heart disease at age older than 45 years in men 
and over 55 years in women with a history of diabetes 
mellitus. Intermediaterisk patients (n=5) of age older than 45 
years in men and 55 years in woman had diabetes mellitus or 
an abnormal baseline ECG. Low-risk patients (n=15) had no 
risk factors. 
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3.3.c. Cardiovascular Screening 
All patients underwent a clinical assessment that included a 
history, physical examination, chest radiograph, 12-lead ECG, 
and transthoracic echocardiogram. An exercise stress test was 
performed on all low-risk patients with normal ECG; those 
who tested positive underwent coronary angiography. 
Myocardial perfusion imaging was performed in patients with 
intermediate risk or with low risk and abnormal baseline ECG 
(left bundle branch block, left ventricular hypertrophy, or ST 
changes, inadequate exercise stress test). Coronary angiograms 
were performed on all high-risk patients and on patients with 
positive myocardial perfusion imaging or positive stress tests. 
Ischemic heart disease was defined as a history of myocardial 
infarction, CABG, PTCA, or the presence of ischemia on 
thallium with exercise. Perfusion imaging findings were 
classified as normal if no perfusion abnormalities were present 
at rest or with exercise; mild if there was decreased uptake in 2 
segments or less; moderate if there was decreased uptake in 3 
to 5 segments; and severe if there were abnormalities in more 
than 5 segments. 
3.3.d.Statistics 
Descriptive statistics in the form of median values and ranges 
for interval variables as well as mean values standard 
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deviation (SD) and frequencies (percentages) for categorical 
variables were performed using the SPSS 14.0 statistical 
package (SPSS Inc., Chicago, Ill., United States). 
 
4. Results 
 
4.1. Validation of a porgnostic function in hungarian 
transplant recipients 
 The range of the estimated 5-year risk of death had a range of 
7%-100%; mean risk was 27.8% and median was 15.3%. 
Table I shows the observed and the expected number of deaths 
and the cumulative incidence of death in deciles of the 
predicted a-year risk of death. The number of subjects in the 
categories was different, and the first 2 deciles were merged in 
1 category because of the many ties. The expected number of 
deaths (94.7) was much higher than the observed number of 
55; the result of the Hosmer-Cemeshow test was significant 
(p<0.001). The function grossly overestimated the risk of 
death in patients with high risk. Acute tubular necrosis and 
vascular calcification were more strongly related, and age, 
serum creatinine level, left ventricular hypertrophy, presence 
of diabetes mellitus, time on dialysis and pretransplant CV 
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disease similarly related to the risk of death in the derivation 
and the validation datasets. Only hemoglobin level had a 
strong and statistically significant association with the risk of 
death when it was added to the model (hazard ratio per 10 g/L: 
0.92, C', 0.86-0.97; p=O.004). Acute tubular necrosis and 
vascular calcification were more strongly related, and age, 
serum creatinine level, left ventricular hypertrophy, presence 
of diabetes mellitus, time on dialysis and pretransplant CV 
disease similarly related to the risk of death n the derivation 
and the validation datasets. Only hemoglobin level had a 
strong and statistically significant association with the risk of 
death when it was added to the model (hazard ratio per 10 g/L: 
0.92, C', 0.86-0.97; p=O.004). 
 
4.2. Prognosis of dialysed patient after transplant grat 
failure 
         The comparison of the HD and the reHD groups revealed 
several differences. Patients in the reHD group had lower 
haemoglobin level and higher GFR. The proportion of patients 
taking statins was larger in the HD group. Patients in the HD 
group were significantly older. In the crude analysis patients in 
the reHD group had a much better survival (hazard ratio 0.51, 
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95% CI: 0.33-0.59). However, after adjustment for age and 
gender there was no difference in the survival probability of 
the two groups (hazard ratio reHD versus HD group: 1.09, 
95% CI: 0.64-1.87). Two patients committed suicide in the 
non-graftectomised group. In 43 patients transplanted kidney 
nephrectomy was performed within 1 year (average: 262 days) 
after restarting HD. Death within 1-year after readmission to 
dialysis was 6.97% in the graftectomised and 21.42 % in non-
graftectomised group. The indications of the graft 
nephrectomy were the followings: acute rejection or severe 
inflammation (in 17 cases), symptoms or signs of severe 
anaemia (in 12 cases), elective nephrectomies without major 
symptoms (diuresis less than 500 ml/day) (in 14 cases). 
Nephrectomised patients had a consistent but statistically not 
significant survival advantage (crude hazard ratio = 0.50 95 % 
confidence interval: 0.22-1.12, p=0.09; after adjustment for 
age and gender hazard ratio: 0.56, 95 % CI: 0.24-1.32, 
p=0.18). Of the reHD patients 34.8 % were re-transplanted, 
although none of them had preemptive re-transplant. Our 
clinical policy for tapering immune suppressive therapy after 
return to dialysis was the following: (1) antiproliferative drugs 
(azathioprine, mycophenolate-mofetil, sirolimus) should be 
the first drugs to be discontinued when irreversible graft 
failure is established, (2) tapering and withdrawal of 
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calcineurin inhibitor over a brief period (1-3 weeks) of the 
graft failure followed a chronic and slow progression, and a 
longer period (4-8 weeks) if the graft failure followed more 
acute immunologic events, (3) slow tapering of steroids with 
possible withdrawal (in a few months) maintaining the same 
dose of steroid for 1 month, then halving the steroid dose in 
every month until complete withdrawal. Histologic 
examination of the resected kidney transplants was available 
for 37 of the 43 cases. In all 37 cases, there was evidence of 
chronic rejection characterized by the existence if variable 
degrees of glomerulitis and tubulitis. Characteristic findings 
included presence of chronic interstitial mononuclear cell 
infiltirate (1), subendothelial lymphocytic and monocytic 
cellular infiltrate (2), intimal vascular fibrosis (3), moderate to 
severe interstitial fibrosis (4). None of the specimens had viral 
inclusions or findings suggestive of an infection. 
 
 
4.3. Cardiovascular screening and management among 
kidney trasnplant candidates in Hungary 
        We put 28 new patients on the wait list between July 
2013 and July 2014. In total, 46 patients were waitlisted at our 
center (hemodialysis: 15%, peritoneal dialysis: 50%, 
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preemptive: 2.3%). The age range of patients was 14 to 73 
years (median: 43.6 years). Eight patients in our study 
population were older than 60 years, 67% were male, and 40% 
were diabetic, with diabetes mellitus as the leading cause of 
endstage renal disease. According to our prespecified protocol, 
15 (54%) patients were identified as low, 5 (18%) as 
intermediate, and 8 (28%) as high risk. Four patients (14%) 
were current smokers. In the low-risk group, we initiated a 
patient education program involving counseling on regular 
exercise such as swimming or cycling to improve patients’ 
functional capacity. In the medium-risk group, we opted for 
medical management, including introduction of beta-blockers, 
angiotensin-converting enzyme inhibitors, statins, and 
ezetimibe, as well as efforts to optimize anemia management, 
indices of bone-mineral disease, and fluid status. In the 
highrisk group, revascularization was done in 5 cases (63%), 
including 3 PTCAs with stents for single-vessel disease, and 
CABG for triple-vessel disease in 2 cases. 
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5. Discussion 
 
        The objective of this study was to gain understanding of 
survival and its modifying factors in transplant recipients at UD 
MHSC. To achieve this, I first validated an existing Spanish 
prognostic function on a group of patients grafted at UD MHSC 
Transplantation Center between 1991 and 15-09-2004; the 
function is used to estimate the risks involved in renal 
transplantation from a compound effect of various predictive 
factors. We assessed the calibration and discrimination 
performance of the function. We concluded that the function 
calibrated well in the low-risk group but it strongly overestimated 
mortality in the high-risk group. The function’s discrimination 
performance is also poor. With this in light, the function we 
assessed cannot be used in clinical practice. Strong predictors 
identified both from the derivation and the validation dataset 
included pre-transplant cardiovascular disease (hazard ratio (HR) 
in our model: 2.5), vascular calcification (HR in our model: 2.2), 
and late graft function (HR in our model: 2.7). In our own dataset, 
length of time on dialysis prior to renal transplantation was found 
to be a less strong predictor. Several factors may explain the 
divergence of these results: different countries use different 
waiting list placement practices in assessing recipient suitability, 
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which results in a tendency where renal transplantation is given to 
kidney disease patients with lower cardiovascular risk and a 
lighter burden of co-morbidities. In a follow-up analysis of a 
French transplantation database on 1585 patients grafted between 
2000 and 2004 at four centers, there was no difference in 5-year 
overall or kidney graft survival between preemptive vs off-dialysis 
renal transplantation, and a multiple Cox model identified no 
increased hazards of death or mortality-adjusted renal graft loss 
associated either with off-dialysis transplantation or with length of 
time on dialysis. The literature reports that post-transplant anemia 
is a significant, independent predictor of death and mortality-
adjusted renal graft loss in kidney transplant recipients. Our study 
has also corroborated this. According to literature data, models 
estimating renal transplantation outcomes should undergo internal 
and external validation before clinical application. In building the 
function, attention must be paid to the number of predictors since 
over-parameterization with too many predictors may bias the 
results. 
      After adjustment for age and sex, we found no significant 
survival differences in patients who returned to dialysis. 
Graftectomy carried no survival benefit in the studied patients. 
      Screening for cardiovascular disease should be performed 
prior to renal transplantation as it has been known since an 
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analysis by Foley that cardiac mortality in dialysis patients is 10 to 
20 times greater than in the average population. Cardiac mortality 
may be reduced to as low as a fraction of this level after successful 
renal transplantation but it still remains at 3 to 5 times above the 
reference range of the average population. In the majority of 
asymptomatic dialysis patients, coronary artery stenoses of 40 to 
50% are found with no intervention following such findings. 
Aggressive risk reduction is warranted in these cases (ACEI, BB, 
statins, antiplatelet therapy). High-risk patients must be identified. 
Stress tests suitable for dialysis patients include stress 
echocardiography and myocardial perfusion imaging 
(scintigraphy). High-risk patients may skip these steps and require 
revascularization (intervention, cardiac surgery). 
 
6. Novel findings 
        We described the survival of a group of patients grafted at 
UD MHSC Transplantation Center between 1991 and 15-09-2004. 
I validated an existing Spanish prognostic function for the first 
time on Hungarian patients. Strong predictors identified both from 
the derivation and the validation dataset included pre-transplant 
cardiovascular disease (hazard ratio (HR) in our model: 2.5), 
vascular calcification (HR in our model: 2.2), and late graft 
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function (HR in our model: 2.7). In our own dataset, length of 
time on dialysis prior to renal transplantation was found to be a 
less strong predictor. 
       After adjustment for age and sex, we found no significant 
survival differences in patients who returned to dialysis. 
Graftectomy carried no survival benefit in the studied patients. 
This conclusion is adaptable also to clinical practice. Preservation 
of the graft as long as possible is a reasonable recommendation: 
by gradual withdrawal of immunosuppression, graft rejection can 
be avoided and donor-specific antibody titer elevation can be 
prevented, since the intact graft will bind antibodies like a 
“sponge”; EPO resistance may also develop with malnutrition-
inflammation syndrome and consequential anemia, which might 
affect success rates of further transplantations. 
     Cardiovascular screening when patients are placed on the 
waiting list is indispensable. In order to reduce early postoperative 
mortality, aggressive risk reduction and intervention specific to 
individual risk groups is recommended prior to transplantation, 
respectively. 
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7. Summary 
 
       My work involved the validation of a published Spanish 
prognostic function for the first time on Hungarian kidney 
transplant recipients. My work has confirmed that such functions 
require validation before clinical use because there is no guarantee 
that they will deliver good performance in patient populations 
other than their derivation dataset. The clinical applicability of the 
studied function is highly limited. In addition to published factors, 
we also assessed the role of other predictors. Beyond the 
predictors not originally included in the model but assessed in our 
investigation (sex, CIT, HLA match, body mass index, 
hemoglobin level), hemoglobin level was the only one to show a 
statistical significant association with survival.  
      More and more patients return to dialysis after renal 
transplantation due to graft failure. These patients have a poorer 
quality of life and their mortality is increased in the first year after 
returning to dialysis. When graft failure develops within one year 
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after transplantation, graftectomy is recommended. In cases when 
graft failure evolves after more than one year and the patient is 
suitable for further transplantation, we recommend keeping the 
graft with a stepwise withdrawal of immunosuppressive therapy. 
Adjusted for sex and age, survival in our patients returning to 
dialysis due to graft failure was no different than that in non-
transplanted dialysis patients.  
      Cardiovascular screening of patients placed on the waiting list 
is paramount since the incidence of acute cardiac events rises in 
the first three months post-transplant, and cardiovascular disease 
is a leading cause of death on the long term in these patients. We 
aimed to reduce classic risk factors in all three risk groups (low, 
medium, high risk) of our patients; we optimized their 
cardioprotective medications and recommended their 
revascularization procedures to be scheduled before 
transplantation whenever possible. By timely management of 
modifiable clinical factors towards their optimal target values, 
reduction of time spent on dialysis and the correction of anemia in 
kidney transplant recipients, the life expectancy of kidney 
transplant recipients can be improved. 
 
Key words: renal transplantation, prognosis, function validation, 
graft failure, cardiovascular screening 
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